

*AMENDMENTS TO THE DRAWINGS*

The attached sheets include changes to Figs. 1-11. Specifically, Figs. 1, 4, 5, 8, 9, 10, 11B, and 11C have been enlarged. Figs. 2, 3, 6, 7A, and 11A have been enlarged and rotated by 90 degrees. As a result of enlarging Figs. 2, 7A, 8, 10, 11B, and 11C, it was necessary to replace the figure labels. In particular, figure labels 2A-B have been replaced with 2A-D, figure label 7A has been replaced with 7A-1 and 7A-2, figure labels 8A-B have been replaced with 8A-C, figure labels 10A-B have been replaced with 10A-G, and figure labels 11B-C have been replaced with 11B-F. The figure labels for each of Figs. 1-11 have been moved from the top of the page to the bottom of the page, and “Figure” has been replaced with “Fig.” In addition, page numbers have been added to Figs. 1-11 (e.g., 1/22).

In Fig. 7A, the following additional changes have been made: (a) the line demarcating the transmembrane region has been shortened such that it extends only over the L at position 72 and no further; (b) the amino acid number designation “77” at the end of the first line of the LT-alpha sequence has been changed to “76”; and (c) the “G” at position 197 of the Neutrokinin-alpha sequence was changed from being white on black to being black on white. An annotated sheet showing the changes to Fig. 7A is attached hereto.

These replacement sheets, which include Figs. 1-11, replace the original sheets including Figs. 1-11.

Attachment: Replacement Sheets

Annotated Sheet Showing Changes

*REMARKS/ARGUMENTS*

Applicants thank Examiner Bunner for the courtesies extended to the undersigned representative during the telephone interview of July 10, 2009. The remarks set forth in the Examiner's "Interview Summary" dated July 14, 2009, reflect the discussion during the Examiner interview.

In accordance with Examiner Bunner's request, replacement drawings are submitted herewith. The Examiner is requested to approve the accompanying replacement drawings.

The changes to the drawings are the enlargement and rotation of some of the figures and the reformatting of the figure labels. In addition, page numbers have been added to the figures.

In Fig. 7A, the following additional changes have been made: (a) the line demarcating the transmembrane region has been shortened such that it extends only over the L at position 72 and no further; (b) the amino acid number designation "77" at the end of the first line of LT-alpha sequence has been changed to "76"; and (c) the "G" at position 197 of Neutrokinne-alpha sequence was changed from being white on black to being black on white. An annotated sheet showing the changes to original Fig. 7A is attached hereto.

The amendment of original Fig. 7A to shorten the length of the line demarcating the transmembrane region brings the drawing into conformity with the description of the transmembrane region as it is defined in the specification in several locations. For example at page 10, lines 20-23, of the specification as originally filed, the transmembrane region is defined as amino acids 47 to 72 of the Neutrokinne-alpha polypeptide.

The amendment of original Fig. 7A to replace the amino acid number designation "77" with "76" corrects the numbering of the sequence such that it agrees with the numbering of the sequence of Lymphotoxin-alpha provided in Gray et al., *Nature*, 312: 721-724 (1984). The aforementioned Gray et al. reference is cited on page 412, line 15, of the specification as originally filed in reference to original Fig. 7A.


The shading of certain amino acid residues in Fig. 7A indicates which amino acid residues match the consensus sequence. The amendment of the "G" at position 197 of

Neutrokin-alpha sequence corrects the shading because a serine (S), and not a glycine (G), residue is the consensus residue at this position. Support for this amendment is found in original Fig. 2B where the G at position 197 of the Neutrokin alpha polypeptide is not shaded.

No new matter has been added by way of these amendments.

Applicants respectfully submit that the patent application is in condition for allowance. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



---

John Kilyk, Jr., Reg. No. 30,763  
LEYDIG, VOIT & MAXER, LTD.  
Two Prudential Plaza, Suite 4900  
180 North Stetson Avenue  
Chicago, Illinois 60601-6731  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: July 15, 2009